TY  - JOUR
AU  - García-Guerrero, Estefanía
AU  - Götz, Ralph
AU  - Doose, Sören
AU  - Sauer, Markus
AU  - Rodríguez-Gil, Alfonso
AU  - Nerreter, Thomas
AU  - Kortüm, K Martin
AU  - Pérez-Simón, José A
AU  - Einsele, Hermann
AU  - Hudecek, Michael
AU  - Danhof, Sophia
PY  - 2020
DO  - 10.1038/s41375-020-0840-y
UR  - http://hdl.handle.net/10668/15467
T2  - Leukemia
AB  - Multiple myeloma (MM) is incurable, so there is a significant unmet need for effective therapy for patients with relapsed or refractory disease. This situation has not changed despite the recent approval of the anti-CD38 antibody daratumumab, one of...
LA  - en
KW  - ADP-ribosyl Cyclase 1
KW  - Antibodies, Monoclonal
KW  - Antibody-Dependent Cell Cytotoxicity
KW  - Antineoplastic Agents
KW  - Cell Line, Tumor
KW  - Drug Synergism
KW  - Gene Expression Regulation, Neoplastic
KW  - Histone Deacetylase 6
KW  - Histone Deacetylase Inhibitors
KW  - Humans
KW  - Hydroxamic Acids
KW  - Immunophenotyping
KW  - Membrane Glycoproteins
KW  - Models, Biological
KW  - Multiple Myeloma
KW  - Pyrimidines
KW  - T-Lymphocyte Subsets
TI  - Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.
TY  - research article
VL  - 35
ER  -